U.S. Luxury Stock News

Earlier this month, Vaxcyte announced it had fully enrolled its OPUS-1 and OPUS-2 Phase 3 trials of VAX-31, a 31-valent pneumococcal conjugate vaccine for adults, and recently published positive Phase 1/2 VAX-31 data in The Lancet Infectious Diseases. These milestones, together with FDA-aligned Phase 3 designs intended to support a future Biologics License Application, underscore VAX-31’s potential to broaden pneumococcal disease coverage versus existing adult vaccines. We’ll now examine how...

Why Dauch (DCH) is on investors' radar today Dauch (DCH) has drawn attention after its recent rebrand from American Axle & Manufacturing Holdings, Inc., a shift that spotlights its role in driveline and metal forming technologies across electric, hybrid, and internal combustion vehicles. See our latest analysis for Dauch. Despite the recent name change, the short term picture has been softer, with a 30 day share price return of 15% and a year to date share price return of 13.6%, while the 1...

Corebridge Financial stock: recent performance snapshot Corebridge Financial (CRBG) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month, past 3 months and year to date, prompting investors to reassess its risk and return trade off. See our latest analysis for Corebridge Financial. At a share price of US$22.30, Corebridge Financial has seen momentum fade recently, with a 30 day share price return of 13.70% decline and a 1 year...

Doximity recently highlighted that its platform now reaches over 80% of U.S. physicians and has delivered annual revenue growth of about 29.3% over the past five years, while generating strong free cash flow that can be used for investment or capital returns. This combination of broad physician adoption and substantial cash generation underscores Doximity’s position as a core digital tool for clinicians and a financially flexible business within healthcare technology. Next, we’ll examine how...

United Therapeutics reported positive phase 3 results from its TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF). The trial met its primary efficacy endpoint and showed significant benefits over placebo with a favorable safety profile. The company plans to seek a supplemental FDA approval to add IPF to the Tyvaso label, supported by integrated data from TETON-1 and TETON-2. For investors watching United Therapeutics, ticker NasdaqGS:UTHR, this news arrives with the...

Wondering if Atlanta Braves Holdings at around US$41.53 is offering good value or just a fan premium? This breakdown is designed to help you see what the current price really represents. The stock has seen a 1% decline over the last 7 days and a 5% decline over the last 30 days, while still showing returns of 4.2% year to date, 3.8% over 1 year, 23.2% over 3 years and 43.2% over 5 years. Recent coverage has focused on the company as a way to gain exposure to a well known sports franchise...

Pinterest recently received a US$1.00 billion investment from affiliates of Elliott Investment Management and used the funds to launch a US$1.00 billion accelerated share repurchase under a broader US$3.50 billion board-approved program, underscoring its focus on capital returns. This move highlights Pinterest’s strong free cash flow profile and signals management’s confidence in the platform’s ability to support shareholder-focused capital allocation. We’ll now examine how this large...

Christopher Hogbin, CEO of Asset Management at Lazard, recently exercised a sizable block of stock options. Following the exercise, he sold a significant portion of common shares, reducing his direct shareholdings. Hogbin still holds a large position in Lazard through outstanding restricted stock units, keeping meaningful exposure to NYSE:LAZ. Lazard, traded on the NYSE under ticker NYSE:LAZ, last closed at $39.11. The share price reflects a 22.7% decline over the past 30 days and a 21.4%...

Wondering if Clearwater Analytics Holdings at around US$23.49 is offering good value right now, or if the price already reflects most of the upside you care about. The stock has been relatively steady in the near term, with a 0.9% return over the last 7 days and 0.4% over the last 30 days, while year to date it shows a 2.6% decline and the 1 year return sits at a 12.4% decline, compared with a 48.6% gain over 3 years. Recent coverage has focused on Clearwater Analytics Holdings as a listed...

With no single headline event driving attention today, JBS (NYSE:JBS) is drawing interest as investors look at its recent share moves and its sizeable global meat processing footprint across beef, pork, poultry, and prepared foods. See our latest analysis for JBS. JBS’s recent 7 day share price return of 13.01% and 90 day share price return of 17.53%, with the stock now at $17.03, suggest momentum has picked up after a quieter 30 day share price return of 0.83%. If the JBS move has you...

Hawaiian Electric Industries (NYSE:HE) has agreed to a $100 million settlement to resolve significant stockholder derivative lawsuits. The payment will be funded by insurers and also partially settles a related securities class action. The agreement is subject to final court approval, with upcoming hearings expected to clarify the remaining legal process. For shareholders watching NYSE:HE at a current share price of $14.67, this settlement addresses a key source of legal uncertainty. The...

Curious if Union Pacific at around US$238.79 is offering fair value or a margin of safety right now? This article walks through the key numbers that matter for you. The stock has seen mixed returns recently, with a 0.2% move over the last 7 days, a 9.9% decline over 30 days, gains of 3.0% year to date and 3.5% over the last year, and gains of 28.2% over 3 years and 19.6% over 5 years. Recent coverage of Union Pacific has focused on its role as a major U.S. railroad operator and how broader...

Xcel Energy (NasdaqGS:XEL) has filed new regulatory materials with the Federal Energy Regulatory Commission focused on dam safety and compliance. The company’s recent correspondence covers dam stability, embankment integrity, and landslide monitoring at its hydro-related facilities. These filings outline ongoing safety measures and responses to federal oversight of critical infrastructure. Xcel Energy, a regulated electric and natural gas utility, depends on reliable generation and...

If you are wondering whether Viavi Solutions at US$34.64 is still attractively priced after a big run, the key question is what that price actually reflects about the business. The stock has delivered returns of 3.1% over the past week, 16.6% over the past month, 90.9% year to date and 209.6% over the last year, with a 225.3% return over three years and 114.0% over five years, which puts recent valuation questions front and center. Recent coverage has focused on Viavi Solutions as a...

Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®. The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials. For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...

In the past week, Best Buy reported quarterly results showing adjusted EPS of US$2.61, up 1.2% year over year, alongside a 0.8% decline in comparable sales and slightly softer-than-expected revenue, while also announcing a 1% increase in its quarterly dividend to US$0.96 per share. Management’s decision to raise the dividend and emphasize scalable profit drivers such as its digital Marketplace and Best Buy Ads highlights a focus on recurring, higher-margin revenue streams even as top-line...

If you are wondering whether Cal-Maine Foods at around US$77.12 is pricing in too much optimism or leaving some value on the table, a closer look at its valuation can help frame that question. The share price is near US$77.12 after a 0.1% move over the last 7 days, with an 11.5% decline over 30 days, a 1.7% decline year to date, a 7.8% decline over 1 year, but a 53.8% gain over 3 years and a 159.0% gain over 5 years. Recent coverage has focused on Cal-Maine Foods as a key player in the US...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Morningstar...

Western Digital joined an open source quantum error correction initiative with Open Quantum Design and QuScript, targeting more reliable quantum computing. The collaboration focuses on setting shared standards and protocols for fault tolerant quantum systems. The move expands Western Digital's role beyond storage into quantum computing reliability and system level error correction. Western Digital (NasdaqGS:WDC) enters this partnership with a share price of $275.34 and very large 1 year and...

Burford Capital recently reported that the US Court of Appeals for the Second Circuit reversed the prior District Court judgment in favor of Petersen and Eton Park in the long-running YPF litigation, prompting the company to review the case’s carrying value and consider a potentially material asset write-down in its upcoming first-quarter results. This reversal directly affects a case that represents a large share of Burford’s fair value assets, underscoring how concentrated legal exposures...

In March 2026, VNET Group, Inc. reported that fourth-quarter 2025 sales rose to CNY 2,687.09 million and net income reached CNY 304.67 million, reversing a net loss a year earlier, while full-year 2025 sales increased to CNY 9,949.26 million despite a net loss of CNY 251.84 million. The company also issued full-year 2026 guidance calling for total net revenues of RMB 11.5–11.8 billion, highlighting management’s confidence in sustaining double-digit growth in its data center business despite...

AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected to list on Nasdaq and will be funded through capital from AnaptysBio and a private placement. The company has added experienced industry executive Susannah Gray to its board as part of the transition. The spin off comes as AnaptysBio, listed as NasdaqGS:ANAB, is in focus with a current share...

Wondering if DocuSign at around US$45.71 is a bargain or still pricing in big expectations? This article walks through what the current share price might be implying about value. The stock has had a mixed run, with a 1.4% return over 30 days, a 29.5% decline year to date, and a 43.8% decline over the last year. These moves can change how the market views both risk and potential reward. Recent coverage has focused on DocuSign's position in digital agreements and how investors are reassessing...

Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with anticipated earnings growth of 15% annually in the coming years. In this dynamic environment, identifying promising small-cap stocks with insider buying can offer unique opportunities for investors seeking potential value amidst fluctuating market conditions.